New anesthesia combo may reduce risks during chest surgery
NCT ID NCT07347496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a newer anesthesia drug, remimazolam, with the standard drug propofol (both combined with a painkiller) for people having chest surgery. The goal is to see if remimazolam causes fewer problems like low oxygen levels or low blood pressure during the operation. About 50 adults aged 18-75 will take part, and their safety and recovery will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients scheduled for elective thoracic surgery (e.g., pulmonary lobectomy, esophagectomy) under general anesthesia with preserved spontaneous respiration. * American Society of Anesthesiologists (ASA) physical status class I-III. * Age between 18 and 75 years. * Provide written informed consent. Exclusion Criteria: * Severe hepatic or renal dysfunction (e.g., Child-Pugh class C, eGFR \< 30 mL/min/1.73m²). * Severe respiratory dysfunction (e.g., COPD GOLD stage 3-4, severe asthma). * Anticipated difficult airway (e.g., Mallampati class IV, history of difficult intubation). * Known allergy or hypersensitivity to benzodiazepines, opioids, or propofol. * Pregnancy or lactation. * Participation in another interventional clinical trial within the past 3 months. * Mental illness or inability to cooperate with assessments.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anesthesia are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery training help frail hearts recover?
- Can a gentler anesthesia cocktail protect a child's developing brain?
- Can a smartwatch outperform standard tools in tracking recovery after surgery?
- Wearables guide home prehab for older lung cancer patients
- Which monitor reads a Child's pain best during surgery?
- Propofol vs. inhaled anesthesia: which one spares your recovery?